PROTAC sEH degrader-5
PROTAC sEH degrader-5 is a highly efficient PROTAC degrader that targets and degrades soluble epoxide hydrolase (sEH) by recruiting cereblon. PROTAC sEH degrader-5 directly inhibits the hydrolase activity of human and mouse sEH, with pIC50 values of 10.36 and 8.41, respectively. PROTAC sEH degrader-5 alleviates LPS (HY-D1056)-induced acute inflammation in vivo. PROTAC sEH degrader-5 can be used in studies related to LPS-induced acute inflammation.
(Pink: Epoxide Hydrolase ligand (HY-113974); Blue: Cereblon ligand (HY-103596); Black: linker).
For research use only. We do not sell to patients.
- CAS No.: 3123230-60-1
- Formula: C53H70N8O10
- Molecular Weight:979.17
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All PROTACs Isoforms
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HepG2 | DC50 |
2.9 nM
|
Degradation of sEH protein in human HepG2 cells assessed via immunoblot after 6 hrs of treatment.
Degradation of sEH protein in human HepG2 cells assessed via immunoblot after 6 hrs of treatment.
|
42469598 |
In Vitro
PROTAC sEH degrader-5 (compound 1d) (0.1-1000 nM; 6-24 h) potently degrades sEH in HepG2 cells via the proteasome pathway, with a DC50 of 2.9 nM, and its activity depends on intact CRBN binding[1].
PROTAC sEH degrader-5 potently inhibits the hydrolase activity of recombinantly purified human sEH (pIC50 = 10.36) and mouse sEH (pIC50 = 8.41)[1].
PROTAC sEH degrader-5 (1 μM; 24 h) induces 61.3 ± 4.7% degradation of sEH in HepG2 cells[1].
sEH degradation induced by PROTAC sEH degrader-5 (100 nM; 24 h) is significantly attenuated by MG132 (HY-13259) (5 μM), whereas Chloroquine (HY-17589A) (5 μM) exerts no obvious effect, indicating that sEH degradation is mediated via the proteasome pathway[1].
The methylated derivative of PROTAC sEH degrader-5 (100 nM; 6 h) with a modified CRBN-binding moiety fails to effectively reduce sEH protein levels, indicating that an intact CRBN-binding moiety is essential for its sEH-degrading activity[1].
PROTAC sEH degrader-5 (100 nM; 6 h) significantly degrades sEH in the cytoplasmic fraction of HepG2 cells, while the level of sEH in the peroxisomal fraction shows no obvious change[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2 cells
-
Concentration:0.1-1000 nM (6 h); 1 μM (24 h); 100 nM (6 h, 24 h with 5 μM MG132 or 5 μM Chloroquine)
-
Incubation Time:6 h; 24 h
-
Result:Achieved 61.3% degradation of sEH at 1 μM for 24 h.
Significantly reduced sEH protein levels at 100 nM for 6 h.
Showed maximal sEH degradation of 73% with a DC50 value of 2.9 nM in concentration-dependent testing over 6 h.
Attenuated sEH degradation when co-treated with 5 μM MG132, but no impact when co-treated with 5 μM chloroquine.
Methylated derivative with disrupted CRBN binding had no effect on sEH abundance.
-
Cell Line:HepG2 cells
-
Concentration:1 μM
-
Incubation Time:24 h; 48 h; 72 h
-
Result:Showed no evident cytotoxicity.
-
Cell Line:HepG2 cells
-
Concentration:1 μM
-
Incubation Time:24 h
-
Result:Showed no significant difference in relative EPHX2 mRNA expression compared to control or DMSO-treated groups.
-
Cell Line:HepG2 cells (cytosolic S10 and peroxisomal P10 fractions)
-
Concentration:100 nM
-
Incubation Time:6 h
-
Result:Reduced sEH protein levels in cytosolic (S10) fraction compared to control groups.
Reduced sEH protein levels in peroxisomal (P10) fraction compared to control groups.
Parmacokinetics
In Vivo
PROTAC sEH degrader-5 (10 mg/kg; i.p.) reduces LPS-induced inflammatory cell infiltration and focal necrosis in the liver[1].
PROTAC sEH degrader-5 (10 mg/kg; i.p.) increases plasma levels of sEH upstream epoxy lipid substrates 9 (10)-EpOME, 12 (13)-EpOME, 11 (12)-EET, 14 (15)-EET and 8 (9)-EET, and elevates the ratios of EpOMEs/DiHOMEs and EETs/DiHETs[1].
PROTAC sEH degrader-5 (10 mg/kg; i.p.) significantly attenuates the LPS-induced upregulation of Il-6, Mcp-1 and Il-10 mRNA expression in the liver[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:LPS-induced acute inflammation[1]
-
Dosage:10 mg/kg
-
Administration:i.p.; 12 h before LPS; samples collected 6 h after LPS
-
Result:Reduced hepatic sEH protein levels.
Attenuated LPS-induced Il-6, Mcp-1, and Il-10 mRNA elevation.
Attenuated hepatic inflammatory cell infiltration and focal necrosis.
Increased plasma epoxy lipid substrates and EpOMEs/DiHOMEs and EETs/DiHETs ratios.
Chemical Information
-
CAS No. 3123230-60-1
-
Molecular Weight 979.17
-
Formula C53H70N8O10
-
SMILES
O=C(NC12C[C@H](C[C@H](C2)C3)C[C@H]3C1)N[C@H]4CC[C@@H](CC4)OC5=CC=C(C=C5)C(N6CCN(CC6)CC(NCCCCCCCCNC(COC7=CC=CC(C(N8C9C(NC(CC9)=O)=O)=O)=C7C8=O)=O)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Carrageenan-Induced Paw Edema
Carrageenan-induced paw edema is an acute inflammation model in which intraplantar injection of carrageenan induces localized inflammatory swelling characterized by vascular permeability, leukocyte infiltration, and production of inflammatory mediators such as prostaglandins and cytokines, making it widely used to evaluate anti-inflammatory agents in vivo. The resulting paw volume or thickness increase is quantified over time as a direct readout of inflammatory intensity and drug efficacy, typically reflecting cyclooxygenase-mediated prostaglandin-driven edema formation and immune cell recruitment in peripheral tissue[20].
-
Zymosan-Induced Peritonitis
Zymosan-induced peritonitis is a sterile acute-inflammation model produced by intraperitoneal injection of zymosan, a yeast cell-wall particle preparation, followed by quantification of leukocyte recruitment and soluble inflammatory mediators in peritoneal lavage fluid. Low-dose zymosan peritonitis is commonly used as a self-resolving acute inflammation model in which neutrophil recruitment occurs early and monocyte/macrophage accumulation follows later. The assay readouts include total peritoneal leukocyte number, differential neutrophil and monocyte/macrophage counts, peritoneal cytokines and chemokines, plasma or peritoneal exudation, and optional lipidomic or metabolomic changes during inflammation and resolution. Early neutrophil recruitment after zymosan depends strongly on complement and mast-cell C5a receptor signaling, whereas later monocyte recruitment is linked to MCP-1/CCL2 production.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- PROTAC sEH degrader-5
- 3123230-60-1
- PROTAC sEH degrader5
- PROTAC sEH degrader 5
- PROTACs
- Epoxide Hydrolase
- recombinant purified human sEH
- mouse sEH
- HepG2 cells
- cytosolic fractions
- proteasome pathway
- peroxisomal fractions
- EPHX2 gene
- LPS-induced acute inflammation
- E3 ubiquitin ligase CRBN
- soluble epoxide hydrolase
- Inhibitor
- inhibitor
- inhibit